Muscarinic Receptor Occupancy and Cognitive Impairment: A PET Study with [11C](+)3-MPB and Scopolamine in Conscious Monkeys

Muscarinic Agonists for the Treatment of Cognition in Schizophrenia

(2016) Angela K. Sellin et al.   CNS SPECTRUMS

M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease

(2009) Antonella Caccamo et al.   Current Alzheimer Research

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

(2008) Anantha Shekhar et al.   AMERICAN JOURNAL OF PSYCHIATRY

Learning and memory impairments in a congenic C57BL/6 strain of mice that lacks the M2 muscarinic acetylcholine receptor subtype

(2008) Natalie K. Bainbridge et al.   BEHAVIOURAL BRAIN RESEARCH

The pedunculopontine tegmental nucleus and the nucleus basalis magnocellularis: Do both have a role in sustained attention?

(2008) Claire L Rostron et al.   BMC NEUROSCIENCE

Scopolamine impairs auditory delayed matching-to-sample performance in monkeys

(2008) Bethany Plakke et al.   NEUROSCIENCE LETTERS

Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717

(2008) R. E. Hampson et al.   PSYCHOPHARMACOLOGY

Muscarinic acetylcholine receptors as CNS drug targets

(2007) Christopher J. Langmead et al.   PHARMACOLOGY & THERAPEUTICS